Related Experiment Videos
Nail changes during docetaxel containing combination chemotherapy
In Sook Woo1, Kon Ho Shim, Gi Young Kim
1Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. insookwoo@catholic.ac.kr
The Korean Journal of Internal Medicine
|September 16, 2004
Summary
Chemotherapy can cause nail toxicity, leading to infections. This report details a case of docetaxel-induced nail problems in Korea that improved with dose reduction.
Area of Science:
- Oncology
- Dermatology
Background:
- Systemic chemotherapy, particularly taxoids, is frequently associated with nail toxicity (onychopathy).
- Nail changes during neutropenia can lead to severe complications like subungual abscesses.
- Despite increasing reports, some chemotherapy studies omit nail toxicity data.
Observation:
- A case of docetaxel-associated onychopathy was observed in a Korean patient.
- The patient experienced nail toxicity during systemic chemotherapy treatment.
- New criteria for evaluating nail toxicity have recently been proposed.
Findings:
- Docetaxel-induced onychopathy was successfully managed by reducing the docetaxel dosage.
- This is the first reported case of docetaxel-associated onychopathy in Korea.
- The case highlights the clinical significance of nail changes in chemotherapy patients.
Implications:
- Dose reduction of docetaxel can be an effective strategy for managing chemotherapy-induced nail toxicity.
- Increased awareness and reporting of nail toxicity in clinical trials are crucial.
- Further research is needed to understand and mitigate taxoid-related onychopathy.